Langerhans cell histiocytosis (LCH) results from an abnormal accumulation of immature Langerhans cells, causing tumor formation or organ damage. Many parts of the body can be affected, including bone, bone marrow, skin, lymph nodes, liver, lung, spleen, and brain. The course of LCH is variable and can range from a self-limited, asymptomatic, localized lesion to a disseminated multisystem disease with a less favorable prognosis.
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A 15-month-old girl presented with a left parietal scalp swelling that had been noted over 3 or 4 days and was increasing in size. There was no history of trauma, fever, or upper respiratory infection. The patient's birth and medical history were unremarkable. Physical examination of the head and neck showed multiple swellings of the temporoparietal region. These were boggy to touch and nontender, with no overlying skin erythema. The rest of the head and neck and chest examination was unremarkable.
A radiographic survey found multiple lytic lesions involving the left superior orbital rim, left anterior fourth rib, and phalanges of the left hand. The largest lesion, in the left parietal bone, measured 3 cm in its greatest diameter, while the remainder of the lesions measured less than 1 cm.
Computed tomography (CT) of the head showed extensive facial, skull base, and calvarial lytic lesions with bony destruction and soft-tissue masses consistent with LCH. There was extensive bilateral lytic destruction involving the temporal bones, with almost complete destructive changes of the mastoid portion and extension up to the external auditory canal (figure 1). There were also bilateral lesions of the petrous temporal bones.
Magnetic resonance imaging (MRI) of the brain showed extensive marrow involvement of the skull base, with the mastoid air cells and middle ear cavities completely replaced by LCH (figure 2). There were also multiple intensely enhancing calvarial lesions. Fine-needle aspiration biopsy of the left parietal mass confirmed the diagnosis of LCH. Blood tests showed a microcytic anemia.
Chemotherapy was started per LCH III protocol, consisting of vinblastine, prednisone, and 6-mercaptopurine for 12 months. A port was placed into the left subclavian vein; this was followed by hoarseness and a left vocal fold paralysis confirmed on endoscopy. MRI at 12 weeks showed improved, but persistent, disease. The child has been healthy and well-appear- LCH most often affects children between the ages of 1 and 3 years but can occur at any age. Its clinical presentation and course are highly variable and can range from a single benign lesion to life-threatening disseminated disease affecting multiple organs. Head and neck involvement occurs in 80% of patients. 1 The most common presentation involving the temporal bone is a mass (70%), followed by otitis media and externa (60%). 2 Chronic otitis media, recurrent otitis externa, stenosis or polyps in the external auditory canal, mastoiditis, and cholesteatoma can be caused by or misdiagnosed for underlying LCH of the temporal bone. The inner ear is less often affected, as the bony labyrinth is typically resistant to erosion by granulation tissue. 3 Imaging modalities such as plain radiography, CT, MRI, positron emission tomography (PET), and bone scan are used to identify, stage, and monitor LCH. CT is useful in delineating bony destruction, whereas MRI is useful in demonstrating soft-tissue and intracranial extension. Therefore, CT and MRI were both used in this child. Bone scan or full skeletal survey is performed to stage LCH. PET has a potential to identify extraskeletal LCH and to evaluate response to treatment.
The natural history of LCH is variable. The factors affecting prognosis are age at presentation (worse in children under 2 years), multisystem involvement, and vital organ dysfunction. 4 With high-risk multisystem disease, as in the case reported, a chemotherapy regimen of vinblastine, prednisone, and 6-mercaptopurine for 12 months per LCH III protocol is indicated.
This case highlights the need to routinely examine the scalp of a child as part of a head and neck examination. The otolaryngologist should have a high index of suspicion when a child presents with scalp swellings as they may be due to extensive lytic destruction of the temporal bones, even without specific ear symptoms.
